AVLN vs EVMN
AVLN: Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases. EVMN: Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates including EVO756 and EVO301.
Side-by-side fundamentals
| Metric | AVLN | EVMN | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $34.56 | $14.07 | |
| Market cap as of 2026-08-11 | $1.5B | $511M | |
| Net margin as of 2026-08-11 | n/a | -606.2% | |
| Operating margin as of 2026-08-11 | n/a | -744.4% | |
| ROE as of 2026-08-11 | -63.8% | -33.5% | EVMN higher |
| ROA as of 2026-08-11 | -57.2% | -30.6% | EVMN higher |
| Debt / equity as of 2026-08-11 | 0.14 | 0.00 | EVMN lower |
| Revenue growth (YoY) as of 2026-08-11 | n/a | +85.7% | |
| Beta as of 2026-08-11 | 1.47 | 0.42 |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.